Ani Pharmaceuticals Stock Performance
| ANIP Stock | USD 59.39 1.53 2.64% |
The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ANI Pharmaceuticals will likely underperform. At this point, ANI Pharmaceuticals has a negative expected return of -0.0661%. Please make sure to confirm ANI Pharmaceuticals' maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if ANI Pharmaceuticals performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ANI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward indicators, ANI Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 2.64 | Five Day Return 5.21 | Year To Date Return 3.85 | Ten Year Return 11.01 | All Time Return (72.22) |
Last Split Factor 1:6 | Last Split Date 2013-07-18 |
1 | Disposition of 3646 shares by Nikhil Lalwani of ANI Pharmaceuticals at 60.51 subject to Rule 16b-3 | 09/06/2024 |
2 | AstraZenecas Calquence sNDA Gets FDA Priority Tag for Expanded Use | 10/03/2024 |
3 | Disposition of 250 shares by Meredith Cook of ANI Pharmaceuticals at 57.19 subject to Rule 16b-3 | 10/14/2024 |
4 | ANI Pharmaceuticals, Inc.s Stock is Soaring But Financials Seem Inconsistent Will The Uptrend Continue | 10/17/2024 |
5 | Earnings Preview ANI Pharmaceuticals Q3 Earnings Expected to Decline | 11/01/2024 |
6 | Compared to Estimates, ANI Q3 Earnings A Look at Key Metrics | 11/08/2024 |
7 | Earnings call ANI Pharmaceuticals Q3 results - revenue up, raises guidance | 11/11/2024 |
8 | Mirums Q3 Earnings Beat Estimates, 2024 Revenue View Raised | 11/12/2024 |
9 | Disposition of 250 shares by Meredith Cook of ANI Pharmaceuticals at 61.36 subject to Rule 16b-3 | 11/13/2024 |
10 | Are Investors Undervaluing ANI Pharmaceuticals Right Now | 11/14/2024 |
11 | Disposition of 6500 shares by Christopher Mutz of ANI Pharmaceuticals at 57.7 subject to Rule 16b-3 | 11/15/2024 |
12 | AbbVies Ovarian Cancer Drug Elahere Gets Approval in Europe | 11/18/2024 |
13 | ANI Upgraded to Buy What Does It Mean for the Stock | 11/20/2024 |
14 | ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference | 11/26/2024 |
15 | Disposition of 5834 shares by Shanmugam Muthusamy of ANI Pharmaceuticals at 66.2 subject to Rule 16b-3 | 11/29/2024 |
| Begin Period Cash Flow | 53.2 M |
ANI |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 6,303 in ANI Pharmaceuticals on August 31, 2024 and sell it today you would lose (364.00) from holding ANI Pharmaceuticals or give up 5.78% of portfolio value over 90 days. ANI Pharmaceuticals is currently does not generate positive expected returns and assumes 2.4028% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than ANI, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ANI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ANI Pharmaceuticals, and traders can use it to determine the average amount a ANI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0275
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANIP |
Estimated Market Risk
| 2.4 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ANI Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ANI Pharmaceuticals by adding ANI Pharmaceuticals to a well-diversified portfolio.
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | -0.016 | ||||
| Return On Asset | 0.0125 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 21.02 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.07 X | ||||
| Price To Sales | 2.25 X | ||||
| Revenue | 486.82 M | ||||
| Gross Profit | 177.6 M | ||||
| EBITDA | 106.6 M | ||||
| Net Income | 18.78 M | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 285.67 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 20.74 X | ||||
| Cash Flow From Operations | 118.96 M | ||||
| Earnings Per Share | (0.47) X | ||||
| Market Capitalization | 1.25 B | ||||
| Total Asset | 904.42 M | ||||
| Retained Earnings | (80.13 M) | ||||
| Working Capital | 374.34 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
About ANI Pharmaceuticals Performance
Assessing ANI Pharmaceuticals' fundamental ratios provides investors with valuable insights into ANI Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ANI Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 223.60 | 184.50 | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.06 | 0.07 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.05 |
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ANI Pharmaceuticals generated a negative expected return over the last 90 days | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.